Internal radiotherapy of painful bone metastases

• Published in: Methods (San Diego, Calif.) Vol. 55; no. 3; pp. 258 - 270
• Main Authors: Liepe, K., Kotzerke, J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2011
• Subjects: 117mTin-DTPA; 153Sm-EDTMP; 186Re-HEDP; 188Re-HEDP; 233Ra; 89Sr; Animals; Bone Neoplasms - complications; Bone Neoplasms - radiotherapy; Bone Neoplasms - secondary; Brachytherapy - methods; Humans; Pain - etiology; Pain - radiotherapy; Painful bone metastasis; Radiopharmaceuticals - administration & dosage; Painful bone metastasis; 153Sm-EDTMP; 233Ra; 89Sr; 117mTin-DTPA; 186Re-HEDP; 188Re-HEDP
• ISSN: 1046-2023; 1095-9130
• DOI: 10.1016/j.ymeth.2011.07.001

► A number of controlled studies have shown a mean response rate in pain relief of 70–80% after internal radiotherapy. ► Internal radiotherapy shows a low rate of side effects. ► The main side effect is a reversible mild bone marrow toxicity. ► Newer data suppose its use as an aggressive first-line treatment. ► Further research should address combination with radiosensitizer or repeated treatment. Internal radiotherapy is effective in the treatment of metastatic bone pain and can improve quality of life. A number of controlled studies using various agents have shown a mean response rate in pain relief of 70–80% of treated patients. Some investigators prefer radionuclides which emit low beta particles for the treatment of bone pain, because the assumption of lower bone marrow toxicity of this agents. However, neither dosimetric data for radiation absorbed dose to the bone marrow nor clinical blood count depression have shown any significant differences between these agents. Other researchers suggest enhanced antitumoral effects using high-energy beta emitters and propose aggressive first-line treatment in the early disease stage instead of using these radiopharmaceuticals only in end-stage patients suffering intractable bone pain. Another approach consists of including other treatment modalities such as autologous stem cell rescue or in combination with chemo or bisphosphonate therapy to a radionuclide treatment scheme. Future research should focus more on the curative effects of combination with radiosensitizer, for example, chemotherapy, or repeated treatments with bone seeking agents.